Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype

Pharmacogenetics

Volumn 6, Issue 3, 1996, Pages 203-211

  Carrière, Véronique ^a   Berthou, François ^b   Baird, Susan ^a   Belloc, Claire ^a   Beaune, Philippe ^a   De Waziers, Isabelle ^a  

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Chlorzoxazone hydroxylase; CYP2E1; Human liver; Phenotype; Polymorphism

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME; OXYGENASE; PHENACETIN;

ALLELE; ARTICLE; CAUCASIAN; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG HYDROXYLATION; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LIVER METABOLISM; METABOLIC ACTIVATION; PHENOTYPE; PRIORITY JOURNAL;

ALLELES; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; GENOTYPE; HUMANS; HYDROXYLATION; PHENOTYPE;

EID: 0029878329     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199606000-00002     Document Type: Article

References (56)

1. Beaune P, Kremers P, Letawe-Goujon F, Gielen JE. Monoclonal antibodies against human liver cytochrome P450. Biochem Pharmacol 1985: 34, 3547-3552.
2. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kalubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993: 14, 1689-1692.
3. Belloc C, Baird S, Lecoeur S, Cosme J, Gautier J-C, Challine D, de Waziers I, Flinois J-P, Beaune PH. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996: 106, 207-219.
4. Berthou F, Flinois J-P, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism in human liver microsomes. Drug Metab Dispos 1991: 19, 561-567.
5. Brockmöller J, Gross D, Kerb R, Drakoulis N, Roots I. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione-S-transferase class Mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992: 43, 647-650.
6. Broly F, Gaedick A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype analysis of common mutations and alleles of CYP 2D6 in European population. DNA cell Biol 1991: 10, 545-558.
7. Carrière V, Goasduff T, Ratanasavanh D, Morel F, Gautier J-C, Guillouzo A, Beaune P, Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993: 6, 852-857.
8. Craddock VM. Nitrosamines and human cancer: proof of an association. Nature 1983: 306, 638.
9. Crespi CL, Langenbach R, Penman BW. Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochrome P450. Toxicology 1993: 82, 89-104.
10. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochrome P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985: 260, 9057-9067.
11. Gautier JC, Urban P, Beaune P, Pompon D. Engineered yeast cells as model to study coupling between human xenobiotic metabolizing enzymes. Eur J Biochem 1993: 211, 63-72.
12. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P450 2E1 induction in alcoholic patients by chlorzoxazone pharmakokinetics. Biochem Pharmacol 1994: 47, 1503-1508.
13. Gorski JC, Wrighton SA, Jones DR, Hall SD. The contribution of cytochrome P450 3A (CYP3A) to the 6-hydroxylation of chlorzoxazone. Sixth North American ISSX meeting. 1994. Raleigh, North Carolina, USA.
14. Guengerich FP. Roles of cytochrome P450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 1988: 48, 2946-2954.
15. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and diseases state using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991: 256, 1189-1194.
16. Guengerich EP, Kim DH, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991: 4, 168-179.
17. Hayashi S-I, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flankng region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991: 110, 559-565.
18. Hirvonen A, Husgafvel-Pursiainen K, Antilla S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer: Dru I and Rsa I restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993: 14, 85-88.
19. Hong J, Yang CS. The nature of microsomal N-nitrosodimethylamine demethylase and its role in carcinogen activation. Carcinogenesis 1985: 6, 1805-1809.
20. Hu Y, Johansson I, Ingelman-Sundberg M. Genetic polymorphism of the human CYP2E1 gene. Characterisation of variant alleles with mutation in exon 2 and in regulatory motifs of the 5′ and 3′ flanking region. 10th International Symposium on Microsomes and Drug Oxidations. 1994. Toronto, Canada.
21. Ingelman-Sundberg M, Johansson I. Mechanisms of hydroxyl radical formation of ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem 1984: 259, 6447-6458.
22. Johansson I, Ingelman-Sundberg M. Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P450. FEBS Lett 1985: 183, 265-269.
23. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, Albano E. Ethanol-inducible cytochrome P450 2E1: genetic polymorphism, regulation and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993: 10, 447-452.
24. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC. Cytochrome P450IIE1 genetic polymorphisms, racial variation and lung cancer risk. Cancer Res 1992: 52, 6712-6715.
25. Kim RB, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 1994: 4, 162-165.
26. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995: 57, 645-655.
27. Kirvistö KT, Under A, Friedel G, Beaune P, Belloc C, Kroemer HK, Fritz P. Immunohistochemical localization of cytochrome P4502E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Archiv 1995: 426, 243-247.
28. Koop DR, Crump BL, Nordblom GD, Coon MJ. Immunochemical evidence for induction of the alcohol-oxidizing cytochrome P-450 of rabbit liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole and isoniazid. Proc Natl Acad Sci USA 1985: 82, 4065-4069.
29. Kremers P, Beaune P, Cresteil T, de Graeve J, Columelli S, Leroux J-P, Gielen JE. Cytochrome P-450 monooxygenase activity in human and rat liver microsomes. Eur J Biochem 1981: 118, 599-605.
30. Lemoine A, Gautier J-C, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux J-P. Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P4503A4 in human liver. Mol Pharmacol 1993: 43, 827-832.
31. Lubet RA, Mayer RT, Cameron JW, Nims RW, Burke MD, Wolff T, Guengerich FP. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys 1985: 238, 43-48.
32. Lucas D, Berthou F, Dréano Y, Lozac'h P, Volcent A, Menez JF. Comparison of levels of cytochromes P450, CYP1A2, CYP2E1 and their related monooxygenase activities in human surgical liver samples. Alcohol Clin Exp Res 1992: 17, 900-905.
33. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
34. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucl Acids Res 1987: 15, 10071.
35. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996: 6, 1-42.
36. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995: 5, 143-150.
37. Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake. Eur J Clin Invest 1989: 19, 549-555.
38. Persson I, Johansson I, Bergling H, Dahl M-L, Seidegard J, Rylander R, Rannug A, Högberg J, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2E1 in Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993: 319, 207-211.
39. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 1990: 3, 566-573.
40. Peyronneau M, Renaud JP, Truan G, Urban P, Pompon D, Mansuy D. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5. Eur J Biochem 1992: 207, 109-116.
41. Sartori E, Delaforge M, Mansuy D. In vitro interaction of rat liver cytochromes P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Biochem Pharmacol 1989: 38, 2061-2068.
42. Shimada T, Yamazaki H, Minura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
43. Song B-J, Gelboin HV, Park S-S, Yang CS, Gonzalez J. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s: transcriptional regulation of the rat enzyme. J Biol Chem 1986: 261, 16689-16697.
44. Stephens EA, Taylor JA, Kaplan N, Yang C-H, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994: 4, 185-192.
45. Tassaneeyakul W, Veronese MO, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in-vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 1993: 46, 1975-1981.
46. Truan G, Cullin C, Reisdorf P, Urban P, Pompon D. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. Gene 1993: 125: 49-55.
47. Tsutsumi M, Lasker JM, Shimizi M, Rosman AS, Lieber CS. The intralobular distribution of ethanol-inducible P450 IIE1 in rat and human liver. Hepatology 1989: 10, 437-446.
48. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T, Satoh K, Motomiya M, Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450 IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 1994: 4, 58-63.
49. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez F. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosomal mapping, and cDNA-directed expression. Biochemistry 1988: 27, 9006-9013.
50. Urban P, Cullin C, Pompon D. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie 1990: 72, 463-472.
51. Watanabe J, Hayashi S-I, Nakachi K, Imai K, Suda Y, Sekine T, and Kawajiri K. Pst I and Rsa I RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucl Acids Res 1990: 18, 7194.
52. Watanabe J, Hayashi S-I, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to Rsa I polymorphism in the 5′-flanking region. J Biochem 1994: 116, 321-326.
53. Wrighton SA, Thomas PE, Molowa DT, Haniu M, Shively JE, Maines SL, Watkins PB, Parker G, Mendez-Picon G, Levin W, Guzelian PS. Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry 1986: 25, 6731-6735.
54. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Rev 1995: 23, 438-440.
55. Yang CS, Yoo JS, Ishizaki H, Hong J. Cytochrome P450IIE1: roles of nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990: 22, 147-159.
56. Yoo JSH, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988: 48, 1499-1504.